Ocata Therapeutics Inc fka OCAT

[john eastman]

Dry AMD announcement

ACT'a January 2011 announcement re FDA has granted the third such approval,
from Dry Age-Related Macular Degeneration (Dry AMD) represents a potential therapy for a $25-30 Billion market opportunity in the US and Europe alone.

There are no approved therapies for Dry AMD currently available.

These are facts and ACT's science is the backbone here.
A solid basis to stand on for the company and the value thereof.